Content Type: Commentary & Opinion

Views from Academia, Industry, Regulatory Agencies, and the Legal System (2nd Ed)

April 9, 2026

New Medicare Payment Policy on Drug Shortages

April 8, 2026

The Case Against Six-Month Limits on Buprenorphine Telehealth Prescribing

April 8, 2026

Clinical Benefit and the Trump Administration’s Cancer Medicine Reforms

April 8, 2026

Bundling Drugs: The Risks Of Combining Copay Assistance

April 8, 2026

Improving Competition to Lower US Prescription Drug Costs

April 8, 2026

The Growing Success of Medicare Drug-Price Negotiation

April 8, 2026

Ensuring Integrity of the Medicaid Drug Rebate Program

April 8, 2026

Law, Politics, and Expert Panels at the US Food and Drug Administration

April 8, 2026

Transparency on Prescription Drug Research Expenditures: A Lever for Restraining Pricing?

March 26, 2026

Patent Law and Policy

March 26, 2026

Data Sharing That Enables Postapproval Drug and Device Research and Protects Patient Privacy: Best Practice Recommendations

March 17, 2026